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PA Kinesin Family Member 6
Variant Is Associated With Coronary
Heart Disease in the Women’s Health Study
Dov Shiffman, PHD,* Daniel I. Chasman, PHD,† Robert Y. L. Zee, PHD,*
Olga A. Iakoubova, MD, PHD,* Judy Z. Louie, BA,* James J. Devlin, PHD,* Paul M. Ridker, MD†‡
Alameda, California; and Boston, Massachusetts
Objectives: We asked if carriers of the 719Arg allele of kinesin family member 6 (KIF6) have increased risk of coronary
heart disease (CHD) in a cohort of initially healthy Caucasian American women.
Background: The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large
population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2
statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention
Study). However, this KIF6 variant was not specifically investigated in the female subgroup in the ARIC study,
and the CARE and WOSCOPS trials included only a small number of female patients.
Methods: Genotypes of the rs20455 single nucleotide polymorphism (SNP) were determined among 25,283 initially
healthy Caucasian women, age 45 years and older, participating in the WHS (Women’s Health Study) who were
prospectively followed over a 12-year period for incident cardiovascular events. The risk associated with the
719Arg allele of KIF6 was estimated using Cox proportional hazards models that adjusted for age and tradi-
tional risk factors.
Results: During follow-up, 953 women suffered a first-ever CHD event (myocardial infarction, coronary revascularization,
or cardiovascular death) or first-ever ischemic stroke. Compared with noncarriers, carriers of the 719Arg allele
had an increased risk of CHD (hazard ratio [HR]  1.24 [95% confidence interval (CI) 1.04 to 1.46, p  0.013])
and myocardial infarction (HR  1.34 [95% CI 1.02 to 1.75, p  0.034]) but not ischemic stroke.
Conclusions: Confirming and extending previous reports, carriers of the 719Arg allele of KIF6 have 34% higher risk of myocar-
dial infarction and 24% higher risk of CHD compared with noncarriers among 25,283 women from the
WHS. (J Am Coll Cardiol 2008;51:444–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.044a
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moronary heart disease (CHD) is known to be affected by
enetic factors (1). For example, it has recently been observed
hat the 719Arg allele of the kinesin family member 6 (KIF6)
See page 456
ene is associated with increased risk of incident CHD events
n ARIC (Atherosclerosis Risk in Communities), a large
opulation-based prospective study of several American com-
unities (2). Carriers of this 719Arg allele of KIF6 were also
ound to have increased risk of incident CHD in the placebo
rom *Celera, Alameda, California; and the †Division of Preventive Medicine and
Division of Cardiology, Center for Cardiovascular Disease Prevention, Brigham and
omen’s Hospital and Harvard Medical School, Boston, Massachusetts. Drs.
hiffman, Iakoubova, and Devlin, and Ms. Louie are employees of Celera and have
wnership interest in Celera. Drs. Shiffman and Chasman contributed equally to this
ork.K
Manuscript received June 13, 2007; revised manuscript received August 27, 2007,
ccepted September 17, 2007.rms of 2 statin trials (3): CARE (Cholesterol and Recurrent
vents) (secondary prevention of CHD) and WOSCOPS
West of Scotland Coronary Prevention Study) (primary pre-
ention of CHD). However, as with any reported genetic
ssociation, replication in additional populations is important
o validate these initial observations (4) and to explore whether
he association can be generalized to other settings.
Kinesins are a large family of proteins involved in
ntracellular transport. Kinesins share a conserved motor
omain that interacts with microtubules and a noncon-
erved tail domain that interacts with a specific cargo either
irectly or through an adaptor protein (5). Kinesins have
een shown to mediate axonal transport in neurons (6), and
ome kinesins have been implicated in the pathogenesis of
euronal diseases, for example, a variant KIF2 was reported
o be associated with schizophrenia (7), KLC1 with Alzhei-
er’s disease (6), and KIF5A with spastic paraplegia (8).
IF6 is expressed in many tissues and cell types, including
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January 29, 2008:444–8 KIF6 Trp719Arg in WHSascular cells (9). However, the role of kinesins in CHD
nd, more specifically, the roles of KIF6 and the Trp719Arg
ariant in CHD are not understood.
Two of the studies that provided early evidence for the
ssociation between the KIF6 719Arg allele and increased risk
f CHD included mainly male patients. One study, CARE,
ncluded mostly male patients, and the other study,
OSCOPS, did not include any women. Thus, we sought to
onfirm the association between this kinesin polymorphism
nd vascular risk in a large prospective cohort of women.
ethods
tudy design. The primary study population was derived
rom participants in the WHS (Women’s Health Study), a
andomized, double-blind, placebo controlled 2  2 facto-
ial design trial of aspirin and vitamin E in the prevention of
ardiovascular disease conducted among initially healthy
omen age at least 45 years at enrollment, who were
ollowed over a mean 12-year period for incident vascular
vents (10). At enrollment, participants provided baseline
linical and demographic information; 28,345 WHS partic-
pants also provided adequate blood samples for both plasma
nd genetic analysis. Participants were followed for the
ccurrence of first-ever myocardial infarction (MI), isch-
mic stroke, coronary revascularization procedures, or
ardiovascular-related death. The CHD end point is a
omposite of MI, coronary revascularization, or cardiovas-
ular death. The methods of cohort assembly, follow-up,
nd end-point validation have been described elsewhere (10).
ll participants provided written informed consent, and the
tudy protocol was approved by the Institutional Review Board
f Brigham and Women’s Hospital (Boston, Massachusetts).
Genotypes for rs20455 (KIF6 Trp719Arg) in WHS
articipants were determined by a previously described
rocedure that combined polymerase chain reaction ampli-
cation of target sequences from 3 ng of genomic deoxyri-
onucleic acid with subsequent allele-specific oligonucleo-
ide ligation as described (2). The ligation products of the 2
lleles were separated by hybridization to product-specific
ligonucleotides, each coupled to spectrally distinct Lumi-
ex 100 xMAP microspheres (Luminex, Austin, Texas).
he captured ligation products were fluorescently labeled
ith streptavidin R-phycoerythrin (Prozyme, San Leandro,
alifornia), sorted on the basis of microsphere spectral
roperties, and detected by a Luminex 100 instrument. The
raction of samples with successful genotype determination
as 97.9%. A total of 25,283 Caucasian women with
vailable deoxyribonucleic acid samples also had full ascer-
ainment for rs20455 genotype, age, and incident cardio-
ascular events.
tatistical methods. Deviations from Hardy-Weinberg
quilibrium (HWE) were evaluated using a log-likelihood
atio test. Clinical covariate differences between carriers and
oncarriers were assessed by the Wilcoxon rank sum test for
ontinuous variables and by a chi-square test of proportions cor categorical characteristics.
ssociation between the 719Arg
llele and the risk of incident
isease was tested with Cox pro-
ortional hazards models ad-
usted for age or traditional risk
actors (age, blood pressure, his-
ory of diabetes, smoking status,
amilial history of MI, low-
ensity lipoprotein cholesterol
LDL-C], and high-density li-
oprotein cholesterol [HDL-C])
sing a pre-specified dominant
nheritance model. Analyses were
dditionally adjusted for randomized treatment assignment
ithin the WHS either to aspirin, vitamin E, or placebo.
otential interaction between traditional risk factors and
19Arg carrier status was tested in separate Cox models that
ncluded the interaction (cross-product) term between the
isk factor and carrier status; these models also included
ain effect terms for carrier status and age. For the
aucasian participants of WHS, there was at least 80%
ower to detect a significant (p  0.05) association between
arriers of the rs20455 risk allele (719Arg) of KIF6 and
ncident cardiovascular disease for hazard ratios of 1.25 or
igher for CHD, and 1.42 or higher (for MI or stroke).
esults
he frequency of the 719Arg allele of rs20455 in the
aucasian participants of WHS was 0.36, which is similar
o that reported for other Caucasian populations (0.36 in
RIC; 0.36 in the CARE cohort; 0.34 in the control group
f the WOSCOPS nested case-control study). The geno-
ype distribution of rs20455 in the Caucasian WHS partic-
pants deviated slightly from HWE expectations (p 
.047), principally because the heterozygous group con-
ained 146 more individuals (1.2% more) than expected.
his deviation is unlikely to be due to genotyping error,
ince the genotype concordance in 628 duplicate samples in
HS was 99.5%. Additionally, the genotype distribution
id not deviate from HWE expectations in ARIC, where
he genotypes for this SNP were determined using the same
echnology used in WHS (2).
Baseline clinical characteristics, including traditional risk
actors for cardiovascular disease (age, blood pressure, his-
ory of diabetes, familial history of MI, smoking status,
DL-C, and HDL-C) did not differ between carriers of the
19Arg allele and noncarriers (Table 1).
During follow-up, 953 of the Caucasian women with
scertained rs20455 genotype suffered a first-ever CHD
vent (MI, coronary revascularization, or cardiovascular
eath) or first-ever ischemic stroke. The cumulative inci-
ence of CHD and MI events was higher among carriers of
he KIF6 719Arg allele than in noncarriers (Fig. 1). The
Abbreviations
and Acronyms
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
HWE  Hardy-Weinberg
equilibrium
LDL-C  low-density
lipoprotein cholesterol
Lp(a)  lipoprotein(a)
MI  myocardial infarctionumulative incidence of CHD events was 2.94% in carriers
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KIF6 Trp719Arg in WHS January 29, 2008:444–8nd 2.51% in noncarriers (log-rank p  0.043), and the
umulative incidence of MI events was 1.23% in carriers and
.94% in noncarriers (log-rank p  0.032). For carriers of
he 719Arg allele compared with noncarriers, the age-
djusted hazard ratio (HR) was 1.18 for CHD (95%
onfidence interval [CI] 1.01 to 1.37, p  0.037) and 1.32
or MI (95% CI 1.03 to 1.69, p  0.028) (Table 2). These
Rs were somewhat increased by adjustment for traditional
isk factors, aspirin treatment, and vitamin E treatment: for
HD the fully adjusted HR was 1.24 (95% CI 1.04 to 1.46,
 0.013) and for MI the fully adjusted HR was 1.34 (95%
I 1.02 to 1.75, p  0.034). We investigated potential
nteraction between KIF6 carrier status and each of the
ollowing risk factors: age (60 years), diabetes, or smoking
tatus; however, we did not observe any significant interactions
p 0.09). The risk for ischemic stroke did not differ between
arriers of the 719Arg allele and noncarriers (age-adjusted HR
1.08; 95% CI 0.85 to 1.37, p  0.52). However, the 95%
aseline Characteristics of WHS Caucasian KIF6 719Arg Noncarrie
Table 1 Baseline Characteristics of WHS Caucasian KIF6 719A
Clinical characteristics (U)
Age (yrs)
BMI (kg/m2)
History of hypertension
Framingham systolic/diastolic blood pressure categories (mm Hg)
120/75
120/75 to 129/84
130/85 to 139/89
140/90 to 159/94
160/95
Family history of MI
Current smoking
History of diabetes
HRT
Menopause
Lipid biomarkers (U)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
ApoB (mg/dl)
HDL cholesterol (mg/dl)
ApoA (mg/dl)
Triglycerides (mg/dl)
Lp(a) (mg/dl)
Inflammation biomarkers (U)
CRP (mg/l)
ICAM (ng/ml)
Fibrinogen (mg/l)
Other biomarkers (U)
Creatinine (mg/dl)
Homocysteine (mol/dl)
HbA1c (%)
alues are number of participants (%) or median (interquartile range).
ApoA apolipoprotein A; ApoB apolipoprotein B; BMI body mass index; CRP C-reactive p
CAM  intracellular adhesion molecule; LDL  low-density lipoprotein; Lp(a)  lipoprotein(a); MIonfidence intervals suggest that 719Arg homozygotes may beFigure 1 Risk of CHD or MI
Comparison of Kaplan-Meier estimates of the cumulative incidence of coronary
heart disease (CHD) events and myocardial infarction (MI) events among carri-
ers of the KIF6 719Arg allele and noncarriers. Log-rank p values are for mean
follow-up time of 12 years.rs and Carriers
rg Noncarriers and Carriers
Noncarriers Carriers p Value
52 (48.0–59.0) 53.0 (48.0–59.0) 0.49
24.8 (22.4–28.3) 24.9 (22.5–28.3) 0.34
2,534 (24.8) 3,702 (24.6) 0.61
0.31
3,406 (33.7) 5,031 (33.8)
3,242 (32.1) 4,859 (32.6)
1,889 (18.7) 2,803 (18.8)
1,321 (13.1) 1,901 (12.8)
240 (2.4) 299 (2.0)
1,212 (13.2) 1,754 (12.9) 0.54
1,207 (11.8) 1,718 (11.4) 0.30
239 (2.3) 405 (2.7) 0.097
4,401 (43.2) 6,609 (43.9) 0.28
5,529 (54.3) 8,246 (54.8) 0.47
208 (184–236) 208 (184–235) 0.44
121.5 (100.6–144.6) 121.3 (100.5–144.4) 0.56
100.2 (84.1–121.8) 100.0 (83.8–121.1) 0.28
51.7 (43.1–62.1) 51.8 (43.2–62.3) 0.64
149.0 (132.1–167.8) 148.9 (132.6–167.8) 0.53
119 (84–176) 118.0 (84.0–175.0) 0.50
10.8 (4.4–33.0) 10.1 (4.2–31.0) 0.002
2.0 (0.8–4.3) 2.0 (0.8–4.4) 0.36
341.9 (302.0–396.0) 343.9 (301.7–394.0) 0.59
349.9 (306.8–402.7) 349.8 (307.2–400.5) 1.00
0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.50
10.5 (8.7–13.0) 10.5 (8.7–12.9) 0.41
5.0 (4.8–5.2) 5.0 (4.8–5.2) 0.11
rotein; HbA1c hemoglobin A1c; HDL high-density lipoprotein; HRT hormone replacement therapy;
 myocardial infarction; WHS  Women’s Health Study.
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January 29, 2008:444–8 KIF6 Trp719Arg in WHSt elevated risk of ischemic stroke: for 719Arg homozygotes
ompared with 719Trp homozygotes, the fully adjusted HR
as 1.42 (95% CI 0.98 to 2.06, p  0.061).
Except for lipoprotein(a) [Lp(a)] levels, none of the
aseline measurements available for WHS participants (Ta-
le 1) was associated with the 719Arg KIF6 polymorphism
arrier status. Carriers of the 719Arg allele of KIF6 had
odestly lower median baseline plasma levels of Lp(a) than
oncarriers had (10.1 mg/dl for carriers compared with
0.8 mg/dl for noncarriers; p  0.01). However, the risk
stimates for CHD (age- and Lp(a)-adjusted HR  1.18;
5% CI 1.01 to 1.38, p  0.043) and MI (age- and
p(a)-adjusted HR  1.30; 95% CI 1.00 to 1.68, p 
.047) were not appreciably changed by adjustment for
aseline Lp(a) levels.
iscussion
e have confirmed the pre-specified hypothesis that Cau-
asian carriers of the 719Arg allele of KIF6 had increased
isk of CHD and MI in the WHS. This finding extends
reviously reported associations between this KIF6 variant
nd CHD (Table 3). Carriers of the 719Arg allele were
reviously reported to be at increased risk of CHD in the
ssociation of KIF6 Trp719Arg With CHD, MI, and Ischemic Stroke
Table 2 Association of KIF6 Trp719Arg With CHD, MI, and Isch
Genotype n Events HR
CHD
ArgArg 3,249 95 1.18
ArgTrp 11,831 349 1.14
ArgArg  ArgTrp 15,080 444 1.18
TrpTrp 10,203 256 R
MI
ArgArg 3,249 37 1.21
ArgTrp 11,831 149 1.35
ArgArg  ArgTrp 15,080 186 1.32
TrpTrp 10,203 96 R
Stroke
ArgArg 3,249 48 1.35
ArgTrp 11,831 130 1.01
ArgArg  ArgTrp 15,080 178 1.08
TrpTrp 10,203 112 R
Adjusted for age, blood pressure, history of diabetes, smoking status, familial history of myocard
nd vitamin E treatment; †hazard ratio and 2-sided p values estimated using Cox proportional ha
CHD  coronary heart disease; CI  confidence interval; HR  hazard ratio.
ssociation Between KIF6 719Arg and Risk of CHD*
Table 3 Association Between KIF6 719Arg and Risk of CHD*
Study Risk Ratio* 95% CI p Value
ARIC 1.09† 1.00–1.19 0.05
CARE 1.50 1.05–2.15 0.03
WOSCOPS 1.55 1.14–2.09 0.005
WHS 1.24 1.04–1.46 0.013
Risk ratios are hazard ratios for CARE (Cholesterol and Recurrent Events), WHS (Women’s Health
f WOSCOPS (West of Scotland Coronary Prevention Study); †In CARE, WOSCOPS, and WHS, the
nheritance model, in which the hazard ratios for carriers of 1 or 2 copies of the 719Arg allele were 1.09
Abbreviations as in Table 1.lacebo arms of the CARE and WOSCOPS statin trials
3). These 2 trials were designed to study mostly male
opulations at high risk for CHD; CARE, a secondary
revention trial, included only individuals (mostly men)
ho had already experienced an MI: the incidence of MI or
HD death in the placebo arm was 13.2% during 5 years of
ollow-up (11); WOSCOPS included only men who had
igh LDL-C levels and other traditional risk factors: the
vent rate was 15.8 events (MI and CHD death) per 1,000
erson-years (12). In contrast, the female participants in the
HS were healthy at baseline and free of prevalent cardio-
ascular disease, as evidenced by the relatively low event
ate: 2.3 CHD events per 1,000 person-years. The 719Arg
llele of KIF6 was also associated with increased risk of
HD in ARIC (2), a prospective study of middle-aged
mericans. Thus, carriers of the 719Arg allele of KIF6 have
ncreased risk of CHD in 4 studies that cover men and
omen and a spectrum of CHD risk—from high risk in
ARE and WOSCOPS to low risk in WHS.
The availability of a panel of lipid and inflammatory
iomarkers assessed among the over 25,000 Caucasian
HS participants allowed us to ask whether the effects of
19Arg on CHD could be understood in terms of corre-
Stroke
djusted for Age Fully Adjusted*
CI)† p Value HR (95% CI)† p Value
1.50) 0.16 1.25 (0.96–1.61) 0.092
1.35) 0.11 1.23 (1.03–1.47) 0.020
1.37) 0.037 1.24 (1.04–1.46) 0.013
ce Reference
1.77) 0.32 1.15 (0.75–1.77) 0.53
1.74) 0.023 1.39 (1.05–1.83) 0.022
1.69) 0.028 1.34 (1.02–1.75) 0.034
ce Reference
1.90) 0.080 1.42 (0.98–2.06) 0.061
1.30) 0.96 1.99 (0.75–1.31) 0.93
1.37) 0.52 1.11 (0.86–1.42) 0.42
ce Reference
rction, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, aspirin treatment,
odels.
Context
Prospective cohort study of middle-age men and women
Placebo arm of a statin secondary prevention study of men (86.5%) and women
Placebo arm of a statin primary prevention study of men
Prospective cohort study of healthy women
and ARIC (Atherosclerosis Risk in Communities), and odds ratio for the nested case-control study
tios are for carriers compared with noncarriers. In ARIC, the risk ratio was based on an additiveemic
A
(95%
(0.93–
(0.97–
(1.01–
eferen
(0.83–
(1.04–
(1.03–
eferen
(0.96–
(0.78–
(0.85–
eferen
ial infaStudy),
risk raor 1.19, respectively (2).
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KIF6 Trp719Arg in WHS January 29, 2008:444–8ponding effects on these biomarkers for traditional and
merging risk factors for CHD (13). We found that the
nly risk factor associated with the KIF6 719Arg carrier
tatus was Lp(a) levels. This association is unlikely to
xplain the association between 719Arg and CHD, since
ower plasma levels of Lp(a) were found among carriers of
he risk allele of KIF6 (719Arg) than among noncarriers,
hereas higher plasma levels of Lp(a) are typically associ-
ted with increased risk of CHD (14). Moreover, the CHD
isk estimates of the 719Arg allele did not appreciably
hange after adjustment for plasma Lp(a) levels. However,
he association with Lp(a) could plausibly reflect an effect of
he KIF6 variant on intracellular transport processes in-
olved in the assembly or secretion of Lp(a).
onclusions
e found that the 719Arg allele of KIF6 is associated with
HD and MI in WHS, a population of initially healthy
aucasian women with a relatively low CHD event rate.
his is the fourth prospective study in which the KIF6
19Arg allele has been associated with increased risk of
HD. Replication of this association in independent pro-
pective population studies would be of great interest.
eprint requests and correspondence: Dr. Dov Shiffman, Celera,
401 Harbor Bay Parkway, Alameda, California 94502. E-mail:
ov.shiffman@celera.com.
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